| Patents for A61P 13 - Drugs for disorders of the urinary system (56,135) |
|---|
| 05/02/2002 | WO2002034753A2 Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 05/02/2002 | WO2002034747A1 Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same |
| 05/02/2002 | WO2002034741A2 A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL)ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE HYDROCHLORIDE |
| 05/02/2002 | WO2002034726A2 Pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 05/02/2002 | WO2002034721A1 Acylsemicarbazides and their use as cyclin dependent kinase (cdk) inhibitors |
| 05/02/2002 | WO2002034718A1 Amide derivatives as nmda receptor antagonists |
| 05/02/2002 | WO2002034716A2 Pyrrolidine modulators of ccr5 chemokine receptor activity |
| 05/02/2002 | WO2002034303A1 Methods of treating vascular diseases characterized by nitric oxide insufficiency |
| 05/02/2002 | WO2002034279A1 Oral preparation containing seaweed for reduction of plaque and calculus |
| 05/02/2002 | WO2002034250A1 Fat emulsions |
| 05/02/2002 | WO2001098330A3 A RECOMBINANT CELL LINE EXPRESSING GPCRx11 AS A FUNCTIONAL RECEPTOR VALIDATED BY ANGIOPEPTIN AND USEFUL FOR SCREENING OF AGONISTS AND ANTAGONISTS |
| 05/02/2002 | WO2001096397A3 Cd154 variants and uses thereof |
| 05/02/2002 | WO2001077137A9 Albumin fusion proteins |
| 05/02/2002 | WO2001072778A3 Method of identifying inhibitors of tie-2 |
| 05/02/2002 | WO2001064749A3 Method for preparing anti-mif antibodies |
| 05/02/2002 | WO2001062923A3 Transporters and ion channels |
| 05/02/2002 | WO2001061008A3 Polypeptides and nucleic acids encoding same |
| 05/02/2002 | WO2001034767A3 22 human secreted proteins |
| 05/02/2002 | WO2001018172A3 Fibroblast growth factor-like polypeptides |
| 05/02/2002 | US20020052504 N-((2-cyclopropoxy-5-(1H-tetrazol-1-))phenyl)methyl-2-(4 -phenyl)piperidin-3-amine and derivatives; in particular as neurokinin-1 receptor antagonists; analgesics; migraines; antiinflammatory, anxiolytic, emetic agents; antidepressants |
| 05/02/2002 | US20020052495 Pyramidine or triazine derivatives which specifically inhibit the binding of endothelin to the receptor |
| 05/02/2002 | US20020052443 Non-antigenic branched polymer conjugates |
| 05/02/2002 | US20020052404 Compositions and methods for treating or preventing diseases of body passageways |
| 05/02/2002 | US20020052392 Have utility as, inter alia, hypoglycemic, and anti-obesity agents. |
| 05/02/2002 | US20020052386 Pyrimidine derivatives |
| 05/02/2002 | US20020052378 Novel compounds and compositions as protease inhibitors |
| 05/02/2002 | US20020052356 Quinoline and quinazoline derivatives; prophylaxis or treatment of arthritis, cardiovascular diseases, diabetes, renal failure and particularly eating disorders and obesity. |
| 05/02/2002 | US20020052352 Treating a malignant tumor, like a melanoma, using plant-derived compounds |
| 05/02/2002 | US20020052341 Bupropion metabolites and methods of their synthesis and use |
| 05/02/2002 | US20020052340 Treating disorders ameliorated by inhibition of neuronal monoamine reuptake, such as erectile dysfunction, affective disorders, cerebral function disorders, cigarette smoking, and incontinence. |
| 05/02/2002 | US20020052337 Composition and method for inhibiting platelet aggregation |
| 05/02/2002 | US20020052333 Therapeutic use of cis-element decoys in vivo |
| 05/02/2002 | US20020052326 Treating diabetes and related diseases in combination with one, two or more other antidiabetic agents and/or one, two or more hypolipidemic agents. |
| 05/02/2002 | US20020052323 Protease inhibitors, particularly for caspase enzyme; treating arthritis, ALS, MS, and the like. |
| 05/02/2002 | US20020052320 Sustained peptide-release formulation |
| 05/02/2002 | US20020051811 Method and composition for masking mineral taste |
| 05/02/2002 | EP1202065A1 Net, a transcription factor of the TCF family, as regulator of angiogenic expression. |
| 05/02/2002 | EP1201639A2 Lipoxin compounds and their use in treating cell proliferative disorders |
| 05/02/2002 | EP1200831A1 Modulating binding site on potassium channels used for screening |
| 05/02/2002 | EP1200596A2 Human synthetases |
| 05/02/2002 | EP1200595A2 Myxoma virus genes for immune modulation |
| 05/02/2002 | EP1200593A2 The il-1l1 gene and polypeptide products |
| 05/02/2002 | EP1200590A1 C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof |
| 05/02/2002 | EP1200587A2 Receptors and associated proteins |
| 05/02/2002 | EP1200582A2 Human proteins having hydrophobic domains and dnas encoding these proteins |
| 05/02/2002 | EP1200579A2 Antisense therapy for hormone-regulated tumors |
| 05/02/2002 | EP1200447A1 Oxazinocarbazoles for the treatment of cns diseases |
| 05/02/2002 | EP1200446A1 OXATHIEPINO 6,5- i b /i ]DIHYDROPYRIDINES, AND RELATED COMPOSITIONS AND METHODS |
| 05/02/2002 | EP1200445A1 Thienopyranecarboxamide derivatives |
| 05/02/2002 | EP1200442A1 2,3-benzodiazepine derivatives |
| 05/02/2002 | EP1200431A2 Quinuclidine derivatives and their use as muscarinic m3 receptor ligands |
| 05/02/2002 | EP1200422A2 Pyrazole compositions useful as inhibitors of erk |
| 05/02/2002 | EP1200406A1 Cyclic amides and imides having selective antagonist activity at alpha-1d adrenergic receptor |
| 05/02/2002 | EP1200402A1 Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain |
| 05/02/2002 | EP1200400A1 Substituted pyrrolidin-2,3,4-trion-3-oxime derivatives useful as nmda-receptor antagonists |
| 05/02/2002 | EP1200399A1 Vitamin d3 analogs |
| 05/02/2002 | EP1200106A1 Composition containing extracts of butyrospermum parkii and the use as medicament or dietary supplement |
| 05/02/2002 | EP1200085A1 Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents |
| 05/02/2002 | EP1089726B1 Composition comprising ss-hydroxy-ss-methylbutyric acid and at least one amino acid |
| 05/02/2002 | CA2678256A1 Methods of treating vascular diseases characterized by nitric oxide insufficiency |
| 05/02/2002 | CA2427085A1 Transmembrane proteins |
| 05/02/2002 | CA2426007A1 A novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride |
| 05/02/2002 | CA2425288A1 Pyrrolidine modulators of ccr5 chemokine receptor activity |
| 05/02/2002 | CA2425283A1 Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 05/02/2002 | CA2425280A1 Pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 05/02/2002 | CA2421885A1 Methods of treating vascular diseases characterized by nitric oxide insufficiency |
| 05/02/2002 | CA2420164A1 Acylsemicarbazides and their use as cyclin dependent kinase (cdk) inhibitors |
| 05/01/2002 | CN1347415A Tricyclic pyridine N-oxides vasopressin agonists |
| 05/01/2002 | CN1347414A Triazole compounds with dopamine-D3-receptor affinity |
| 05/01/2002 | CN1347411A Sulfonamide derivs. having oxadiazole rings |
| 05/01/2002 | CN1347408A Use of maduraphthalazine derivs. as inhibitors of pro-inflammatory cytokins |
| 05/01/2002 | CN1347326A BAFF, inhibitors thereof and their use in modulation of B-cell response |
| 05/01/2002 | CN1347325A Novel amide derivs. as growth hormone secretagogues |
| 05/01/2002 | CN1083838C Novel imidazole derivs., method for preparing same, use as medicine, and pharmaceutical compositions contg. same |
| 05/01/2002 | CN1083715C Use of insulin sensitisers for treating renal diseases |
| 04/30/2002 | US6380405 Taxane prodrugs |
| 04/30/2002 | US6380374 Isolated nucleic acid; culture product |
| 04/30/2002 | US6380360 Polycystic kidney disease 1 gene and uses thereof |
| 04/30/2002 | US6380258 Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds |
| 04/30/2002 | US6380251 Therapy of ocular hypertension which comprises administering cyclopentane heptan(ene)oic acid or its 2-thiocarbamoyloxy and 2-carbamoyloxy derivatives |
| 04/30/2002 | US6380250 Therapy of ocular hypertension which comprises administering cyclopentane heptan(ene)oic acid or its 2-thiocarbamoyloxy and 2-carbamoyloxy derivatives |
| 04/30/2002 | US6380238 Indoline derivatives as 5-HT2B and or 5-HTC receptor ligands |
| 04/30/2002 | US6380235 Useful as progesterone receptor agonists and antagonists, used for contraception, in therapy of fibroids, endometriosis, breast, uterine, ovarian and prostate cancer, and post menopausal hormone replacement therapy |
| 04/30/2002 | US6380195 Including (methylenedioxyphenyl)cyclopenteno(1,2-b)pyridine derivatives |
| 04/30/2002 | US6380184 For increased production of wool, milk, and meat by treating animals with therapeutically effective amount of compound |
| 04/30/2002 | US6380183 Treatment of diseases involving cyst formation |
| 04/30/2002 | US6380167 Methods for anti-tumor therapy |
| 04/30/2002 | US6379927 Retinoblastoma fusion proteins |
| 04/30/2002 | US6379913 A polypeptide encoding an amino acid sequence; prevention and therapy for diabetes, inflammatory glomerulonephritis, ischemis renal failure, artherosclerosis, coronary vasoconstriction and ischemic heart disease |
| 04/30/2002 | US6379691 Supplying to tissues of vascular system |
| 04/25/2002 | WO2002033100A2 Regulation of human adenylate cyclase, type iv |
| 04/25/2002 | WO2002033099A2 Human kinases |
| 04/25/2002 | WO2002033090A2 Pharmaceutical preparations and methods for inhibiting tumors |
| 04/25/2002 | WO2002033079A2 Human g-protein coupled receptor and uses thereof |
| 04/25/2002 | WO2002032961A2 Novel polypeptides and nucleic acids encoding same |
| 04/25/2002 | WO2002032960A2 Methods of selecting compounds for modulation of bladder function |
| 04/25/2002 | WO2002032901A2 Bridged piperazine derivatives |
| 04/25/2002 | WO2002032900A2 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents |
| 04/25/2002 | WO2002032897A1 Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists |
| 04/25/2002 | WO2002032883A1 Novel 4-benzyloxyphenyl derivative and use thereof |